Skip to Main Content

Paper Details

The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Clin Genitourin Cancer
16
2020
Everolimus, Lenvatinib, Metastatic Renal Cell Carcinoma, PATIENTS, Patients, VEGF, everolimus, lenvatinib, mRCC, metastatic renal cell carcinoma, patients, rapamycin, tyrosine, tyrosine kinase, vascular endothelial growth factor
Author NameAffiliation
James J HsiehWashington University School of Medicine
James J HsiehWashington University School of Medicine
  • 1 - 2

Datasets

Release 1.2